Four Distinct Subtypes of Gastric Cancer Found

The study also found higher levels of the JAK2 gene in patients with the EBV-positive subtype, suggesting that certain gastric cancers could be susceptible to JAK2 inhibitors, such as ruxolitinib. However, at this point, studies are not currently examining JAK2 inhibition in this disease type. An earlier study did explore AZD1480 with gastric cancer; however, development of this compound was discontinued.

Amplifications in Pd-L1/2 in the EBV-positive subtype indicate that checkpoint inhibitors directed toward these ligands could be effective. A phase I study is investigating the PD-L1 inhibitor MPDL3280A in patients with solid tumors or hematologic malignancies. Patients with gastric cancer will be enrolled in this study, although it is not specifically looking for the EBV-positive subtype. The chromosomally unstable category represented the largest subtype, with these tumors generally being located in the areas between the stomach and esophagus. Bass noted that these tumors have a striking number of genomic amplifications of key cancer-promoting genes.

This finding result opens up an entirely new line of research to allow us to investigate what underlies this deadly form of gastric cancer and to ultimately develop new therapies. The NCI and the National Human Genome Research Institute, which are run by the National Institutes of Health (NIH), manages TCGA. In a press release concerning the results, the director of the NIH characterized the EBV findings as groundbreaking.

This study reinforces the value of the approach we are using to study genomic diversity and similarity among tumors of many different cancer types. Only such a systematic analysis could have yielded observations about the association betweenEbv and several provocative molecular characteristics.

In July, the PI3K delta inhibitor idelalisib gained approval in combination with rituximab as a treatment for patients with chronic lymphocytic leukemia. Additionally, several other PI3K inhibitors are in development. A phase I study exploring the investigational PI3K inhibitor BYL719 in combination with the Hsp90 inhibitor AUY922 is currently enrolling patients with metastatic gastric cancer.

Recently, Novo Nordisk announced that the European Commission has granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. Xultophy® was approved in Switzerland on 12 September 2014, and Novo Nordisk expects to launch it in the first European countries in the first half of 2015.

Xultophy® is a once-daily, single injection combination product consisting of insulin degludec (Tresiba®), a once-daily basal insulin analogue with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. Xultophy® has shown consistent results in improving glycemic control in insulin deficient people with type 2 diabetes. In addition, Xultophy® also showed a great effect on weight decreasing in obese patients.

Xultophy® really represents a new paradigm with the potential to transform how type 2 diabetes is treated. Once-daily injection obviously provides convenience and reduces suffering for type 2 diabetes patients. Meanwhile, the action on weight control of Xultophy® will improve glucose tolerance in insulin sensitive tissues. So, the new diabetes drug Xultophy® particularly be available to the type 2 diabetes and obesity patients.

Numerologist Warda is hooked on OG-L002 fishing, collecting. And lastly her encouragement comes from socializing along with her companions.